The approach to measuring psoriatic arthritis (PsA) is still very variable. However, consistently assessed disease activity enables the determination, documentation and communication of treatment success or failure and facilitates the comparison of outcomes between trial populations and real-life patients. Consequently, homogeneously applied measures are desirable to optimise patient care. In the following, we present a brief overview of single disease activity measures and compound scores for PsA.